Cancer treatment-induced bone loss (CTIBL) in prostate cancer: Pathophysiology, preclinical findings, and treatment with zoledronic acid

Theresa A. Guise, James A. Eastham

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Androgen deprivation therapy (ADT) is the treatment of choice for men with advanced prostate cancer, and the most common indication for the initiation of ADT is a rising serum prostate-specific antigen level after failed local therapy. Consequently, potentially long periods of androgen suppression exist in these patients, resulting in clinically significant bone loss. This review will discuss the pathophysiology of cancer treatment-induced bone loss (CTIBL) and the treatment and prevention of CTIBL with zoledronic acid. Relevant information was identified through searches of published studies, abstracts from scientific meetings, and review articles. The treatment of prostate cancer patients with surgical or pharmacologic ADT results in the activation of osteoclast-mediated bone resorption, leading to reductions in bone mineral density (BMD) and increased fracture risk. Preclinical evidence from a murine prostate cancer model also suggests that ADT may potentially increase the risk of bone metastasis. Bone loss caused by long-term ADT and bone metastases can result in significant skeletal morbidity in patients with prostate cancer. Zoledronic acid has been shown to increase BMD in prostate cancer patients receiving ADT, and is the only bisphosphonate effective in reducing the risk of skeletal complications in prostate cancer patients with bone metastases in the setting of hormone-refractory disease. In addition, preclinical evidence suggests that zoledronic acid may prevent tumor metastasis to bone. Zoledronic acid can provide clinical benefit for patients with advanced prostate cancer throughout the course of their disease. In these patients BMD should be monitored routinely, and zoledronic acid treatment should be considered to prevent bone loss.

Original languageEnglish (US)
Pages (from-to)46-54
Number of pages9
JournalEuropean Urology, Supplements
Volume3
Issue number5 SPEC. ISS.
DOIs
StatePublished - Nov 2004

Fingerprint

zoledronic acid
Prostatic Neoplasms
Bone and Bones
Androgens
Neoplasms
Therapeutics
Bone Density
Neoplasm Metastasis

Keywords

  • Bisphosphonates
  • Bone loss
  • Prostate cancer
  • Zoledronic acid

ASJC Scopus subject areas

  • Urology

Cite this

Cancer treatment-induced bone loss (CTIBL) in prostate cancer : Pathophysiology, preclinical findings, and treatment with zoledronic acid. / Guise, Theresa A.; Eastham, James A.

In: European Urology, Supplements, Vol. 3, No. 5 SPEC. ISS., 11.2004, p. 46-54.

Research output: Contribution to journalArticle

@article{556d349679bc4669b402114695215d2e,
title = "Cancer treatment-induced bone loss (CTIBL) in prostate cancer: Pathophysiology, preclinical findings, and treatment with zoledronic acid",
abstract = "Androgen deprivation therapy (ADT) is the treatment of choice for men with advanced prostate cancer, and the most common indication for the initiation of ADT is a rising serum prostate-specific antigen level after failed local therapy. Consequently, potentially long periods of androgen suppression exist in these patients, resulting in clinically significant bone loss. This review will discuss the pathophysiology of cancer treatment-induced bone loss (CTIBL) and the treatment and prevention of CTIBL with zoledronic acid. Relevant information was identified through searches of published studies, abstracts from scientific meetings, and review articles. The treatment of prostate cancer patients with surgical or pharmacologic ADT results in the activation of osteoclast-mediated bone resorption, leading to reductions in bone mineral density (BMD) and increased fracture risk. Preclinical evidence from a murine prostate cancer model also suggests that ADT may potentially increase the risk of bone metastasis. Bone loss caused by long-term ADT and bone metastases can result in significant skeletal morbidity in patients with prostate cancer. Zoledronic acid has been shown to increase BMD in prostate cancer patients receiving ADT, and is the only bisphosphonate effective in reducing the risk of skeletal complications in prostate cancer patients with bone metastases in the setting of hormone-refractory disease. In addition, preclinical evidence suggests that zoledronic acid may prevent tumor metastasis to bone. Zoledronic acid can provide clinical benefit for patients with advanced prostate cancer throughout the course of their disease. In these patients BMD should be monitored routinely, and zoledronic acid treatment should be considered to prevent bone loss.",
keywords = "Bisphosphonates, Bone loss, Prostate cancer, Zoledronic acid",
author = "Guise, {Theresa A.} and Eastham, {James A.}",
year = "2004",
month = "11",
doi = "10.1016/j.eursup.2004.08.012",
language = "English (US)",
volume = "3",
pages = "46--54",
journal = "European Urology, Supplements",
issn = "1569-9056",
publisher = "Elsevier",
number = "5 SPEC. ISS.",

}

TY - JOUR

T1 - Cancer treatment-induced bone loss (CTIBL) in prostate cancer

T2 - Pathophysiology, preclinical findings, and treatment with zoledronic acid

AU - Guise, Theresa A.

AU - Eastham, James A.

PY - 2004/11

Y1 - 2004/11

N2 - Androgen deprivation therapy (ADT) is the treatment of choice for men with advanced prostate cancer, and the most common indication for the initiation of ADT is a rising serum prostate-specific antigen level after failed local therapy. Consequently, potentially long periods of androgen suppression exist in these patients, resulting in clinically significant bone loss. This review will discuss the pathophysiology of cancer treatment-induced bone loss (CTIBL) and the treatment and prevention of CTIBL with zoledronic acid. Relevant information was identified through searches of published studies, abstracts from scientific meetings, and review articles. The treatment of prostate cancer patients with surgical or pharmacologic ADT results in the activation of osteoclast-mediated bone resorption, leading to reductions in bone mineral density (BMD) and increased fracture risk. Preclinical evidence from a murine prostate cancer model also suggests that ADT may potentially increase the risk of bone metastasis. Bone loss caused by long-term ADT and bone metastases can result in significant skeletal morbidity in patients with prostate cancer. Zoledronic acid has been shown to increase BMD in prostate cancer patients receiving ADT, and is the only bisphosphonate effective in reducing the risk of skeletal complications in prostate cancer patients with bone metastases in the setting of hormone-refractory disease. In addition, preclinical evidence suggests that zoledronic acid may prevent tumor metastasis to bone. Zoledronic acid can provide clinical benefit for patients with advanced prostate cancer throughout the course of their disease. In these patients BMD should be monitored routinely, and zoledronic acid treatment should be considered to prevent bone loss.

AB - Androgen deprivation therapy (ADT) is the treatment of choice for men with advanced prostate cancer, and the most common indication for the initiation of ADT is a rising serum prostate-specific antigen level after failed local therapy. Consequently, potentially long periods of androgen suppression exist in these patients, resulting in clinically significant bone loss. This review will discuss the pathophysiology of cancer treatment-induced bone loss (CTIBL) and the treatment and prevention of CTIBL with zoledronic acid. Relevant information was identified through searches of published studies, abstracts from scientific meetings, and review articles. The treatment of prostate cancer patients with surgical or pharmacologic ADT results in the activation of osteoclast-mediated bone resorption, leading to reductions in bone mineral density (BMD) and increased fracture risk. Preclinical evidence from a murine prostate cancer model also suggests that ADT may potentially increase the risk of bone metastasis. Bone loss caused by long-term ADT and bone metastases can result in significant skeletal morbidity in patients with prostate cancer. Zoledronic acid has been shown to increase BMD in prostate cancer patients receiving ADT, and is the only bisphosphonate effective in reducing the risk of skeletal complications in prostate cancer patients with bone metastases in the setting of hormone-refractory disease. In addition, preclinical evidence suggests that zoledronic acid may prevent tumor metastasis to bone. Zoledronic acid can provide clinical benefit for patients with advanced prostate cancer throughout the course of their disease. In these patients BMD should be monitored routinely, and zoledronic acid treatment should be considered to prevent bone loss.

KW - Bisphosphonates

KW - Bone loss

KW - Prostate cancer

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=7244243990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7244243990&partnerID=8YFLogxK

U2 - 10.1016/j.eursup.2004.08.012

DO - 10.1016/j.eursup.2004.08.012

M3 - Article

AN - SCOPUS:7244243990

VL - 3

SP - 46

EP - 54

JO - European Urology, Supplements

JF - European Urology, Supplements

SN - 1569-9056

IS - 5 SPEC. ISS.

ER -